Domestic reference pricing may reduce Medicare expenditures on new drugs, study finds

By | September 24, 2021
Basing new drug launch prices on historical domestic data could limit manufacturers’ power to set extremely high launch prices and could reduce Medicare spending on new drugs by up to 30%, according to a new white paper released today by West Health and its Council for Informed Drug Spending Analysis.